绿康生化(002868) - 2022 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2022 was ¥89,802,349, representing a 14.68% increase compared to the same period last year[5]. - Total operating revenue for Q3 2022 was ¥234,068,484.09, a decrease of 7.5% compared to ¥252,150,180.35 in the same period last year[37]. - The net profit attributable to shareholders was -¥31,243,901.96, a decrease of 149.22% year-on-year[5]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥28,126,768.03, a decline of 539.52% compared to the previous year[5]. - Net loss for Q3 2022 was ¥68,093,068.62, compared to a net loss of ¥6,130,103.51 in Q3 2021, reflecting a significant decline in profitability[38]. - The total comprehensive income for the third quarter was -68,093,068.62 CNY, with a loss attributable to the parent company of -67,776,031.12 CNY[39]. - Basic and diluted earnings per share were both -0.44 CNY, compared to -0.04 CNY in the previous period[39]. Assets and Liabilities - Total assets at the end of the reporting period were ¥1,267,040,394.85, an increase of 0.69% from the end of the previous year[5]. - The company's total assets increased slightly to ¥1,267,040,394.85 from ¥1,258,398,896.70, showing stability in asset base despite losses[35]. - Total liabilities increased to ¥613,111,256.49 from ¥536,376,689.72, reflecting a growing debt burden[35]. - The company's cash and cash equivalents decreased from ¥97,495,450.53 to ¥34,717,251.56, indicating a liquidity challenge[34]. Cash Flow - The company's cash flow from operating activities showed a net outflow of -¥13,515,864.69, a significant decrease of 4,342.38%[5]. - Cash inflow from operating activities totaled 302,118,093.41 CNY, an increase from 283,909,384.26 CNY in the previous period[42]. - The net cash flow from operating activities was -13,515,864.69 CNY, a significant decrease from 318,591.85 CNY in the previous period[42]. - Cash outflow from investing activities was 122,549,264.25 CNY, down from 242,961,229.25 CNY in the previous period[42]. - The net cash flow from financing activities was 69,264,478.11 CNY, compared to 164,938,738.37 CNY in the previous period[42]. - The ending balance of cash and cash equivalents was 34,717,251.56 CNY, down from 121,971,243.74 CNY in the previous period[42]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 9,457[16]. - Shanghai Kangyi Investment Co., Ltd. holds 30.43% of shares, totaling 47,291,400 shares, with 8,000,000 shares pledged[16]. - He Li (Asia) Investment Co., Ltd. holds 26.70% of shares, totaling 41,489,860 shares[16]. - The top ten shareholders include several domestic and foreign entities, with significant stakes held by Shanghai Kangyi and He Li Investment[17]. Investment and Acquisitions - The company plans to issue up to 46,624,751 shares in a non-public offering, which will not exceed 30% of the total share capital before the issuance[19]. - The total amount of funds to be raised from the non-public offering is expected to be no more than 305 million RMB[19]. - The acquisition of 100% equity in Jiangxi Wei Ke New Materials Technology Co., Ltd. is contingent upon the successful completion of the share transfer and asset sale[24]. - The deadline for the asset acquisition agreement has been extended to November 28, 2022, allowing for further negotiations[26]. - The company has suspended the share transfer and asset sale due to the need for further discussions among involved parties[25]. - The asset transfer is subject to audit and evaluation, with the transaction price yet to be determined, posing risks of termination if agreements cannot be reached[29]. - The asset acquisition agreement stipulates that if the transaction price is below 95 million yuan, the counterparty has the right to terminate the agreement[29]. Operational Challenges - The company's inventory increased by 72.52% to ¥105,587,860.43, indicating a rise in product stock at the end of the period[9]. - Accounts receivable increased to ¥55,386,102.48 from ¥44,031,827.95, suggesting potential issues with collections[34]. - Inventory levels rose significantly to ¥105,587,860.43 from ¥61,204,853.85, indicating potential overstocking or declining sales[34]. - The company reported a substantial increase in financial expenses, with interest expenses rising to ¥8,205,399.45 from ¥1,387,033.25[38]. - The company has not reported any net profit from mergers under common control, indicating no contribution from such activities[35]. Regulatory and Compliance - The non-public offering was approved by the China Securities Regulatory Commission (CSRC) on June 16, 2021[21]. - The approval for the non-public offering expired due to the inability to complete the issuance within 12 months, but it will not significantly impact the company's operations[22]. - The company has extended the validity period for the non-public offering resolution until February 18, 2023[21]. - The company has not yet issued a new notice for the shareholders' meeting regarding the share transfer, indicating significant uncertainty about approval[28]. - The implementation of the share transfer and asset sale is interdependent; failure of one will prevent the execution of the others[29]. - The company emphasizes the importance of timely information disclosure to investors regarding the progress of these transactions[26].